<DOC>
	<DOCNO>NCT02933697</DOCNO>
	<brief_summary>The Study open-labeled , randomize control trial , phase IIIb . Its objective ass safety factor Xa inhibitor apixaban versus vitamin-K antagonist ( VKA ) phenprocoumon patient NVAF ESKD hemodialysis . The safety assess mean incidence major clinically relevant , non-major bleeding anticoagulation .</brief_summary>
	<brief_title>Compare Apixaban Vitamin-K Antagonists Patients With Atrial Fibrillation ( AF ) End-Stage Kidney Disease ( ESKD )</brief_title>
	<detailed_description>AXADIA investigator‐driven , prospective , parallel‐group , single country , multi‐center phase IIIb trial ass safety apixaban versus vitamin-K antagonist phenprocoumon patient NVAF ESKD hemodialysis treatment . The trial conduct 25-30 site Germany . The primary goal study assess safety two type oral anticoagulant patient ESKD hemodialysis non-valvular atrial fibrillation ( NVAF ) . The novel FXa inhibitor apixaban ( reduce dose 2x 2.5 mg/day ) compare vitamin-K antagonist ( VKA ) phenprocoumon ( target range : International Normalized Ratio ( INR ) 2.0-3.0 ) regard bleed rate chronic administration prevention stroke systemic embolism . The primary hypothesis study oral anticoagulation apixaban improve safety significantly reduce bleed rate patient ESKD hemodialysis NVAF compare VKA phenprocoumon . A pharmacokinetic sub-study perform 28 patient included apixaban treatment group evaluate systemic exposure apixaban hemodialysis session special population .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Phenprocoumon</mesh_term>
	<criteria>Endstage kidney disease ( ESKD ) chronic hemodialysis treatment 3 time per week ( 4 hour per dialysis ) Chronic ( i.e . repeat ) paroxysmal , persistent permanent nonvalvular atrial fibrillation ( NVAF ) document standard Holter ECG least 2 separate day ( apart ) hemodialysis procedure Increased risk stroke systemic embolism identify CHA2DS2VASc score 2 indication oral anticoagulation Patients ischemic stroke meet criterion , include 3 month severely handicap ( modified Rankin scale 0 1 6 , i.e . symptom significant disability able carry usual activity , despite symptom ( Farrell , Godwin , Richards , Warlow ( 1991 ) ) Males female , age 18 old AF atrial flutter due reversible cause ( e.g. , thyrotoxicosis , pericarditis ) Patients new onset hemodialysis within last 3 month Clinically significant ( moderate severe ) aortic mitral stenosis Conditions AF require chronic anticoagulation ( e.g. , prosthetic mechanical heart valve ) . Active infective endocarditis Any plan interventional surgical AF atrial flutter ablation procedure Any active bleeding A serious bleeding event previous 6 month screen Inadequately control ( HbA1c level &gt; 8.5 % ) untreated diabetes History malignant neoplasms high risk current bleeding ( see summary product characteristic ( SmPC ) study drug ) Known indication treatment NSAIDs ( see SmPC study drug ) acetylsalicylic acid ( ASA ) 100 mg per day allow Impaired liver function e.g. , cause active infection HIV , HBV HCV , hepatitis liver damage ( No limit ALT AST value define study protocol , although mention SmPC frequently elevate dialysis patient . In case clinically relevant increase ALT AST level , patient 's eligibility decide responsible investigator ) Any type stroke within 3 month prior baseline Other indication anticoagulation NVAF Valvular heart disease require surgery A high risk bleeding ( e.g. , active peptic ulcer disease , platelet count &lt; 100,000 per cubic millimeter hemoglobin level &lt; 8 g per deciliter ) Documented hemorrhagic tendency blood dyscrasias Current alcohol drug abuse Life expectancy less 1 year Indication dual platelet inhibition baseline ( ASA ≤ 100 mg/day allow , clopidrogel exclude dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Kidney disease</keyword>
	<keyword>Anticoagulation</keyword>
</DOC>